Results 61 to 70 of about 21,294 (218)

The hidden regulators: Non‐coding RNAs in KMT2A‐rearranged acute lymphoblastic leukemia

International Journal of Cancer, EarlyView.
Abstract Acute lymphoblastic leukemia (ALL) driven by KMT2A rearrangements (KMT2A‐r) is an aggressive hematologic malignancy with poor prognosis and a high incidence in infants. While KMT2A fusion proteins drive leukemogenesis through transcriptional dysregulation, recent discoveries have highlighted the pivotal role of non‐coding RNAs (ncRNAs) in ...
Maria Augusta Poersch, Ana Carolina Rodrigues, Priscila Elias Ferreira Stricker, Alexandre Luiz Korte Azevedo, Daniel Pacheco Bruschi, Jaqueline Carvalho de Oliveira   +5 more
wiley   +1 more source

Chinese pan‐cancer patient genomic characteristics: A comprehensive analysis based on the National Cancer Center–Clinical Diagnostics Knowledgebase real‐world clinical sequencing cohort

Interdisciplinary Medicine, EarlyView.
We assembled National Cancer Center–Clinical Diagnostics Knowledgebase, a clinical genomic knowledgebase of 6935 tumors with matched normal samples, revealing key somatic alterations and actionable variants (70.2% of the cohort). Enrichment of certain different gene mutations was observed between Chinese and American populations, along with a strong ...
Hongrui Li, Shun Wang, Guowei Zhao, Jiangtao Li, Xin Li, Bingning Wang, Yi Zhang, Mengfei Yao, Lei Guo, Jianming Ying, Wenbin Li   +10 more
wiley   +1 more source

Oncogenic driver mutations in lung cancer [PDF]

, 2013
published_or_final_versio
Lam, CLD, LUO, Y
core   +1 more source

Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer

Exploration of Targeted Anti-tumor Therapy, 2023
Aim: The aim of this study was to investigate the feasibility of developing a deep learning (DL) algorithm for classifying brain metastases from non-small cell lung cancer (NSCLC) into epidermal growth factor receptor (EGFR) mutation and anaplastic ...
Abhishek Mahajan, Gurukrishna B, Shweta Wadhwa, Ujjwal Agarwal, Ujjwal Baid, Sanjay Talbar, Amit Kumar Janu, Vijay Patil, Vanita Noronha, Naveen Mummudi, Anil Tibdewal, JP Agarwal, Subash Yadav, Rajiv Kumar Kaushal, Ameya Puranik, Nilendu Purandare, Kumar Prabhash   +16 more
doaj   +1 more source

Small Nucleotide Variant Analysis Using RNA Fusion Panel (SMURF): Making the Most of RNAseq Data in Solid Tumours

Journal of Clinical Laboratory Analysis, EarlyView.
RNA‐based fusion panels using targeted next‐generation sequencing of formalin‐fixed paraffin‐embedded (FFPE) tumour tissue specimens have been used for a few years from patients with various tumour types to detect rearrangements/fusions. Using the bioinformatic approaches the data obtained from RNA sequencing (RNAseq) can also be used for small ...
Pranav Dorwal, Julie Robin, Broden Krause, Patricia Pyrchla, Bin Yuan, Robert Quach, Anna Fong Na Goh, Pamela Htain, Noel Djitro, Amit Kumar, Liyan Song, Priscillia Siswara, Suzanne Svobodova, Peter Kaub, Beena Kumar   +14 more
wiley   +1 more source

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib

Journal of Oncological Sciences, 2018
Concomitant mutations of echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) can be found rarely in lung adenocarcinoma.
Mehmet Artaç, Levent Korkmaz, Mustafa Karaağaç, Buğra Kaya, Necdet Poyraz, Hakan Özön, Zehra Er, Lema Tavlı   +7 more
doaj   +1 more source

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib

Frontiers in Oncology, 2023
BackgroundAlthough anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have impressive response in advanced lung adenocarcinoma with anaplastic lymphoma kinase (ALK) fusion, no guidelines point to the potential benefits of neoadjuvant ALK ...
Xiaoqian Zhai, Ting Wang, Yiyun Lin, Jiabi Zhang, Yuqing Wang, Weiya Wang, Qinghua Zhou, Daxing Zhu   +7 more
doaj   +1 more source

Protein glycosylation in lung cancer from a mass spectrometry perspective

Mass Spectrometry Reviews, EarlyView.
Abstract Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi, Simon Sugár, Lilla Turiák   +2 more
wiley   +1 more source

Antisymmetrization of a Mean Field Calculation of the T-Matrix

, 1994
The usual definition of the prior(post) interaction $V(V^\prime )$ between projectile and target (resp. ejectile and residual target) being contradictory with full antisymmetrization between nucleons, an explicit antisymmetrization projector ${\cal A ...
A. Ohnishi, A. Weiguny, A. Wierling, A.B. Volkov, B. G. Giraud, B.G. Giraud, B.G. Giraud, B.G. Giraud, B.G. Giraud, E.W. Schmid, F. Mekideche, F. Tanabe, H. Friedrich, H. Horiuchi, H. Horiuchi, H. Reinhardt, J. C. Lemm, J. Stoer, N. Austern, N. Ohtsuka, P. Bonche, T. Maruyama, Y.C. Tang   +22 more
core   +1 more source

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

Current Oncology, 2022
STRN-ALK fusion is a rare ALK rearrangement identified in non-small cell lung cancer (NSCLC) patients. Here, we reported a case of lung adenocarcinomas with brain metastasis, harboring STRN-ALK fusion, responded well to ensartinib. This case report could
Linlin Zhang, Ping Xiao, Fanlu Meng, Diansheng Zhong   +3 more
doaj   +1 more source